-
J Clin Psychopharmacol · Aug 2015
Randomized Controlled Trial Multicenter StudyAssessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.
- Zubin Bhagwagar, Anne Torbeyns, Delphine Hennicken, Ming Zheng, Boadie W Dunlop, Sanjay J Mathew, Arif Khan, Richard Weisler, Craig Nelson, Richard Shelton, Michael E Thase, and Roger Lane.
- From *Bristol-Myers Squibb Company, Wallingford, CT; †Bristol-Myers Squibb Company, Braine-l'Alleud, Belgium; ‡Emory University, Atlanta, GA; §Baylor College of Medicine, Houston, TX; ∥Northwest Clinical Research Center, Bellevue, WA; ¶Department of Psychiatry, Duke University School of Medicine, Durham; #Department of Psychiatry, Duke University Medical Center, Durham; **Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC; ††University of California, San Francisco, CA; ‡‡University of Alabama at Birmingham, Birmingham, AL; and §§University of Pennsylvania, Philadelphia, PA.
- J Clin Psychopharmacol. 2015 Aug 1; 35 (4): 454-9.
AbstractTwo phase 2B, randomized, double-blind studies assessed the efficacy and safety of fixed or flexible dose of triple monoamine uptake inhibitor BMS-820836 in patients with treatment-resistant depression to demonstrate whether switching to BMS-820836 was superior to the continuation of standard antidepressant treatment. Patients with a history of inadequate response to 1 to 3 adequate trials of antidepressant therapies were prospectively treated with duloxetine 60 mg/d for 8 weeks (CN162-006) or duloxetine 60 mg/d or escitalopram 20 mg/d for 7 weeks (CN162-007). Inadequate responders were randomized to continue their prospective phase treatment or switch to flexible-dose (0.5-2 mg/d; CN162-006) or fixed-dose (0.25, 0.5, 1, or 2 mg/d; CN162-007) BMS-820836 for 6 weeks. The primary end point in both studies was mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from randomization to study end point. BMS-820836 flexible (0.5-2 mg/d) or fixed dose of 1 mg/d or greater showed efficacy similar to the continuation of antidepressant treatment, with no statistically significant or clinically meaningful differences. In the CN162-006 study, the adjusted mean (SE) change in MADRS total score was -8.7 (0.661) and -8.1 (0.656) for BMS-820836 and duloxetine, respectively (P = 0.526). In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). Thus, BMS-820836 was well tolerated, with no evidence of dose-dependent discontinuations due to adverse events, but it failed to demonstrate superiority to the continuation of an existing antidepressant in patients with treatment-resistant depression.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.